Literature DB >> 29569965

Analysis of risk factors for cervical lymph node metastases in patients with sporadic medullary thyroid carcinoma.

Weina Fan1, Cheng Xiao2, Fusheng Wu1.   

Abstract

Objective Medullary thyroid carcinoma (MTC) is classified as either sporadic or inherited. This study was performed to analyze the risk factors for cervical lymph node metastases and predict the indication for prophylactic lateral neck dissection in patients with sporadic MTC. Methods Sixty-five patients with sporadic MTC were retrospectively reviewed. Univariate analysis with the chi-square test and multiple logistic regression analysis were applied to identify the clinicopathological features (sex, age, tumor size, number of tumor foci, capsule or vascular invasion, and others) associated with cervical lymph node metastases. Results The metastasis rates in the central and lateral compartments were 46.2% (30/65) and 40.0% (26/65), respectively. The incidence of cervical lymph node metastases was significantly higher in patients with a tumor size of >1 cm, tumor multifocality, and thyroid capsule invasion. Only thyroid capsule invasion was an independent predictive factor for central compartment metastases and lateral neck metastases. The possibility of central compartment metastases was significantly higher when the preoperative serum carcinoembryonic antigen concentration was >30 ng/mL (60.0% vs. 34.3%). Conclusions MTC is associated with a high incidence of cervical lymph node metastases. Prophylactic lateral node dissection is necessary in patients with thyroid capsule invasion or a high serum carcinoembryonic antigen concentration.

Entities:  

Keywords:  Thyroid neoplasm; carcinoembryonic antigen; carcinoma; lymph node metastases; medullary; node dissection

Mesh:

Substances:

Year:  2018        PMID: 29569965      PMCID: PMC5991226          DOI: 10.1177/0300060518762684

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


Introduction

Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor of the thyroid gland that is derived from parafollicular C cells and was first described in 1959.[1] It accounts for 5% to 10% of all thyroid cancers and may be classified as either hereditary MTC (25%) or sporadic MTC (SMTC) (75%).[1-4] Parafollicular C cells can produce calcitonin and carcinoembryonic antigen (CEA), which are relatively sensitive and specific markers for both the preoperative diagnosis and follow-up of MTC.[1,5,6] Due to the lack of treatment options other than surgery, the standard treatment for MTC is total thyroidectomy with prophylactic central lymph node dissection in clinically node-negative patients and therapeutic neck dissection in clinically suspicious lymph node-positive patients.[7-10] However, controversy remains surrounding the indication for prophylactic lateral lymph node dissection. This study was performed to analyze the risk factors for cervical lymph node metastases and predict the indication for prophylactic lateral neck dissection in patients with SMTC.

Materials and methods

Study population

We retrospectively studied the medical records of patients who were diagnosed with SMTC from 2007 to 2017 in the First Affiliated Hospital of Zhejiang University, China. All patients underwent preoperative ultrasound (including evaluation of the thyroid bed, central compartment, and bilateral lateral neck), preoperative measurement of CEA levels, and/or computed tomography neck imaging. Patients with a clinical suspicion of SMTC underwent fine-needle aspiration of thyroid nodules. Only patients with postoperative histopathological features consistent with the diagnosis of SMTC were included in the study. We excluded patients with SMTC who had distant metastases. The following characteristics of each patient were recorded: age at diagnosis of SMTC, sex, tumor size, number of tumor foci (unifocality/multifocality), capsule or vascular invasion, lymph node metastases, and extrathyroidal extension of the tumor. According to the National Comprehensive Cancer Network (NCCN) guidelines in 2017, tumor size was categorized as ≥1 cm or <1 cm. Because MTC is often associated with multiple endocrine neoplasia with diagnosis at a younger age, the patients were stratified into two relevant groups: those aged <45 and ≥45 years. The stage of MTC was defined based on the NCCN tumor-node-metastasis (TNM) classification system. All participants were well informed about the aim of the study, and all agreed to participate in the study. The study was approved by the ethics committee of the First Affiliated Hospital of Zhejiang University, Hangzhou, China.

Histopathological examination

All patients’ thyroid glands were available for histopathological examination. After fixation in formalin, the whole thyroid gland was embedded in paraffin. Soft tissue and lymph nodes were processed separately. Conventional staining (hematoxylin and eosin) and calcitonin immunohistochemistry were performed on every surgical specimen using the standard avidin-biotin complex peroxidase approach and a commercial monoclonal antibody (ZSGB-BIO, Beijing, China). The diagnosis of SMTC was confirmed by positive immunostaining for calcitonin and CEA in all patients. Two experienced pathologists assessed the characteristics of the tumor, including the size, unifocality or multifocality, unilaterality or bilaterality, extrathyroidal extension of the tumor, demonstration of lymphatic or vascular invasion, or a combination thereof. The primary tumor diameter was ascertained by direct measurements of the surgical thyroid specimens. When multiple MTCs were present, only the largest tumor was considered. Multifocality was defined as more than one tumor lesion, regardless of unilaterality or bilaterality.

Surgical treatment

The surgical procedure was performed with curative intent in all patients. All patients underwent total thyroidectomy with lymph node dissection of the central neck compartment (level VI). Patients with tumors of ≥1 cm in diameter as well as both clinical and radiological validation of lymph node involvement underwent therapeutic ipsilateral or bilateral modified neck dissection (levels II–V). In contrast, prophylactic central neck dissection was performed for patients with no clinical or radiological evidence of identifiable cervical node metastases.

Statistical analysis

Data analysis was performed using IBM SPSS Statistics, version 22.0 (IBM Corp., Armonk, NY, USA). Data are presented as mean ± standard deviation or median (range), where appropriate. Associations between lymph node involvement and tumor characteristics were evaluated using the chi-square test. Logistic regression analysis was used to identify whether the factors that were significant in the univariate analysis were still statistically significant in the multivariate analysis. In all cases, a p value of <0.05 was considered significant.

Results

In total, 65 patients (27 male, 38 female) with SMTC were included in this study. Their mean age at diagnosis was 49.7 ± 12.6 years (range, 22–76 years). The detailed clinicopathological characteristics of the 65 patients are listed in Table 1. The mean tumor size was 2.0 ± 1.3 cm. Among all 65 patients, 17 (26.2%) were had multifocal tumors and 38 had unifocal tumors. Lymph node metastases were found in 34 of 65 patients (54.3%), including 30 (46.2%) patients with central cervical lymph node involvement and 26 (40.0%) with lateral lymph node metastases. In the absence of positive central cervical lymph nodes, 3 of 65 patients had positive nodes (skip metastases) in the ipsilateral lateral neck compartment. The lateral neck lymph nodes were systematically dissected in 35 patients (53.8%). Three patients with bilateral thyroid lesions underwent bilateral radical lymph node dissection. Upper mediastinal dissection was performed by sternotomy in only one patient with macroscopic central node involvement. According to the NCCN guidelines, pathological TNM staging showed that 19 patients had stage I disease at presentation, 8 had stage II, 7 had stage III, and 31 had stage IV.
Table 1.

Clinicopathological and pathological characteristics of 65 patients with sporadic medullary thyroid carcinoma.

Characteristic
Sex, female/male27/38
Age at diagnosis, years49.7 ± 12.6
Tumor size, cm2.0 ± 1.3
Multifocal tumors17 (26.2)
Thyroid capsule invasion21 (32.3)
Vascular invasion22 (33.8)
Lymph node metastases34 (52.3)
Infiltration of surrounding soft tissues16 (24.6)
CEA level, ng/mL
 <3035 (53.8)
 ≥3030 (46.2)
Pathological TNM stage
 I19 (29.2)
 II8 (12.3)
 III7 (10.8)
 IV31 (47.7)

Data are presented as n, n (%), or mean ± standard deviation. CEA, carcinoembryonic antigen; TNM: tumor-node-metastasis

Clinicopathological and pathological characteristics of 65 patients with sporadic medullary thyroid carcinoma. Data are presented as n, n (%), or mean ± standard deviation. CEA, carcinoembryonic antigen; TNM: tumor-node-metastasis All variables that were of statistical significance in the univariate logistic regression (p < 0.05) were incorporated into a logistic regression analysis model to control for the potential effect of confounding. Univariate analysis with the chi-square test (Table 2) was used to analyze the association of cervical lymph node metastases with sex, age, tumor size, multifocal tumors, thyroid capsule invasion, vascular invasion, and infiltration of surrounding soft tissues. The results showed that patients with a tumor size of ≥1 cm, multifocal tumors, and thyroid capsule invasion had a higher incidence of cervical lymph node metastases. Multivariate regression analyses showed that only thyroid invasion remained significantly associated with cervical lymph node metastases. Tables 3 and 4 show that thyroid capsule invasion was an independent predictive factor for central compartment metastases (p < 0.001; odds ratio, 11.080) and lateral neck metastases (p < 0.001; odds ratio, 9.067). In our cohort, a preoperative CEA level of ≥30 ng/mL was associated with a higher incidence of central cervical lymph node metastases than was a CEA level of <30 ng/mL (60.0% vs. 34.3%, respectively; χ2 = 4.298; p = 0.038). Receiver operating characteristic curves were used to assess the serum CEA level as a predictor of cervical lymph node metastasis of MTC. As shown in Figure 1, the area under the curve was 0.720 (95% confidence interval, 0.592–0.847; p = 0.002).
Table 2.

Univariate analyses of lymph node metastases in patients with sporadic medullary thyroid carcinoma.

FactorsTotal
Central compartment metastases

Lateral compartment metastases
n (%)χ2p[a]n (%)χ2p[a]
Sex
 Male2716 (59.3)3.1920.07414 (51.9)2.7030.100
 Female3814 (36.8)12 (31.6)
Age, years
 ≥454521 (46.7)0.0150.90119 (42.2)0.3010.583
 <45209 (45.0)7 (35.0)
Tumor size
 ≥1 cm4524 (53.3)3.8590.04923 (51.1)8.5470.003
 <1 cm206 (20.0)3 (15.0)
Multifocality
 Yes1713 (76.4)8.5140.00411 (64.7)5.8550.016
 No4817 (35.4)15 (31.3)
Vascular invasion
 Yes228 (36.4)1.2830.2578 (36.4)2.6370.104
 No4322 (51.2)18 (41.9)
Capsule invasion
 Yes2621 (80.8)20.893<0.00120 (76.9)19.752<0.001
 No399 (25.0)6 (15.4)

aResults of chi-square test between lymph node involvement and tumor characteristics.

Table 3.

Multivariate logistic regression analyses for central compartment metastases in patients with sporadic medullary thyroid carcinoma.

FactorsβSEWaldpaOR95% CI
Tumor size0.0760.6481.4330.2312.1730.610–7.744
Multifocality1.4610.7823.4940.0624.3110.931–19.949
Capsule invasion2.4050.65813.372<0.00111.0803.053–40.214

aAccording to multivariate logistic regression analyses. SE, standard error; OR, odds ratio; CI, confidence interval

Table 4.

Multivariate logistic regression analyses for lateral compartment metastases in patients with sporadic medullary thyroid carcinoma.

FactorsβSEWaldpOR95% CI
Tumor size1.0230.6742.3000.1292.7800.742–10.426
Multifocality0.8240.7451.2220.2672.2800.529–9.827
Capsule invasion2.2630.63512.682<0.0019.6072.766–33.374

SE, standard error; OR, odds ratio; CI, confidence interval

Figure 1.

Receiver operating characteristic curve of preoperative carcinoembryonic antigen levels predicting cervical lymph node metastases in patients with sporadic medullary thyroid carcinoma.

Univariate analyses of lymph node metastases in patients with sporadic medullary thyroid carcinoma. aResults of chi-square test between lymph node involvement and tumor characteristics. Multivariate logistic regression analyses for central compartment metastases in patients with sporadic medullary thyroid carcinoma. aAccording to multivariate logistic regression analyses. SE, standard error; OR, odds ratio; CI, confidence interval Multivariate logistic regression analyses for lateral compartment metastases in patients with sporadic medullary thyroid carcinoma. SE, standard error; OR, odds ratio; CI, confidence interval Receiver operating characteristic curve of preoperative carcinoembryonic antigen levels predicting cervical lymph node metastases in patients with sporadic medullary thyroid carcinoma.

Discussion

Neck lymph node metastases are reportedly the main predictor of local recurrence and distant metastases in patients with MTC, mainly in the lungs but also in the liver and bones.[11-14] This indicates that the dissection of metastatic lymph nodes in patients with MTC, if detected and removed completely during the initial surgery, may prevent reoperation for recurrence in the neck. However, accurate estimation of cervical lymph node involvement is largely dependent upon preoperative imaging examination or intraoperative assessment, which are insufficient. According to a survey by Moley and DeBenedetti,[15] intraoperative lymph node assessment by surgeons will miss one-third of clinically involved lymph nodes. Thus, prophylactic neck lymph node dissection provides the best possibility of achieving curative surgery for some clinically node-negative patients. Based on the 2015 American Thyroid Association (ATA) and 2014 British Thyroid Association (BTA) guidelines, standard treatment for MTC should include total thyroidectomy and central lymph node dissection; however, the extent of dissection in the lateral neck compartments and on the side opposite the largest primary thyroid tumor remains controversial.[9,12-14,16,17] The ATA guideline recommends that patients with MTC confined to cervical lymph node metastases should undergo dissection of the involved lateral neck compartments (levels II–V), whereas the BTA guideline recommends that prophylactic lateral neck dissection should be performed in the presence of central compartment node metastases.[9,16,18] The need for prophylactic bilateral lateral compartment node dissection in the presence of central compartment node metastases is still unclear. The ATA suggests using the serum calcitonin level as a reference, but this recommendation does not seem to have been widely accepted because of the uncertainness of patient survival.[9] Considering this background, a thorough understanding of the clinical risk factors is needed to identify high-risk patients requiring prophylactic lateral neck lymph node dissection. Esfandiari et al.[19] reviewed data from 2968 patients with MTC from the National Cancer Database and found a close relationship between tumor size and the likelihood of lymph node metastases; the authors thus suggested that surgeons should decide to perform prophylactic lateral neck lymph node dissection based on the tumor size. Machens et al.[11] found that approximately 70% of patients with central compartment node metastases had lateral compartment node metastases. This finding demonstrates that prophylactic dissection of the ipsilateral neck compartment is necessary for patients with MTC with one positive central lymph node, and the performance of contralateral neck lymph node dissection should depend on histopathologic confirmation of lymph node metastases obtained on fresh frozen section.[11,20] Our retrospective study of 65 consecutive patients with SMTC treated by total thyroidectomy and central or lateral neck dissection confirms that lymph node metastasis is frequent (found in 52.3% of patients in our study). This finding is consistent with other series: cervical lymph node metastases in patients with MTC have been reported to occur in 25% to 63% of patients, whether the primary tumors are <1 cm or >4 cm.[15,21] The univariate analysis in the present study showed that cervical lymph node metastases spread frequently in patients with a tumor size of >1 cm, multifocal tumors, and thyroid capsule invasion, while the multivariate logistic regression analysis demonstrated that only thyroid capsule invasion was an independent predictive factor for cervical compartment metastases. However, in their evaluation of 2968 patients with MTC, Esfandiari et al.[19] found that the percent of metastatic cervical lymph nodes was 43% in patients with a tumor size of <2 cm and 65% in those with a tumor size of >2 cm, indicating a relationship between tumor size and cervical lymph node metastasis. In the present study, the univariate analysis showed that cervical lymph node metastases spread frequently in patients with a tumor size of >1 cm; however, the multivariate logistic regression analysis revealed that tumor size was not an independent predictive factor for cervical compartment metastases. This difference might have been due to our classification of tumor size or our smaller sample cohort. A close multivariate correlation between thyroid capsule invasion and lymph node metastases in patients with MTC was demonstrated, which is consistent with the result reported by Machens et al.[22] This clearly demonstrates that prophylactic lateral neck dissection should be performed during the initial procedure in patients with SMTC with thyroid capsule invasion. From a clinical perspective, this may help to resolve some of the controversy surrounding the indication for prophylactic lateral neck dissection. Calcitonin and CEA levels are fairly powerful biomarkers with which to confirm the diagnosis of MTC.[6,9] According to previous studies, a serum CEA level of ≥30 ng/mL is suggestive of lymph node metastases in the central and lateral neck compartments.[1,7,23] In the present study, we also found that higher stratified basal CEA serum levels reflected the presence of cervical lymph node metastases. Unfortunately, the calcitonin level was not recorded in our whole cohort; therefore, the doubling time of calcitonin, which is known to be a better predictor of cervical lymph node metastases, could not be calculated. This may be the main limitation of our study. Another inherent limitation of this study is that it was retrospective. Unlike in randomized controlled trials, there is also a risk for treatment selection bias.

Conclusion

This study may help to resolve some of the controversy surrounding the indication for lateral lymph node dissection. Prophylactic lateral neck dissection should be performed during the initial procedure in patients with thyroid capsule invasion or a high serum CEA level.
  22 in total

Review 1.  Surgical management of medullary thyroid carcinoma.

Authors:  Agathoklis Konstantinidis; Michael Stang; Sanziana A Roman; Julie Ann Sosa
Journal:  Updates Surg       Date:  2017-04-13

2.  Peak calcitonin cut-off levels for the diagnosis of occult medullary thyroid cancer: evidence of confounding by gender.

Authors:  Andreas Machens; Henning Dralle
Journal:  Clin Endocrinol (Oxf)       Date:  2010-02-23       Impact factor: 3.478

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

4.  Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.

Authors:  Jacques Barbet; Loïc Campion; Françoise Kraeber-Bodéré; Jean-François Chatal
Journal:  J Clin Endocrinol Metab       Date:  2005-08-09       Impact factor: 5.958

5.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer.

Authors:  Andreas Machens; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2010-03-25       Impact factor: 5.958

6.  Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.

Authors:  Ana Luiza Maia; Debora R Siqueira; Marco A V Kulcsar; Alfio J Tincani; Glaucia M F S Mazeto; Lea M Z Maciel
Journal:  Arq Bras Endocrinol Metabol       Date:  2014-10

7.  Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.

Authors:  E Kebebew; P H Ituarte; A E Siperstein; Q Y Duh; O H Clark
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

8.  Medullary thyroid carcinoma: prognostic factors and treatment.

Authors:  P Rougier; C Parmentier; A Laplanche; M Lefevre; J P Travagli; B Caillou; M Schlumberger; J Lacour; M Tubiana
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-02       Impact factor: 7.038

9.  Prediction of lateral lymph node metastases in medullary thyroid cancer.

Authors:  A Machens; S Hauptmann; H Dralle
Journal:  Br J Surg       Date:  2008-05       Impact factor: 6.939

10.  The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer.

Authors:  Nazanene H Esfandiari; David T Hughes; Huiying Yin; Mousumi Banerjee; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2013-11-25       Impact factor: 5.958

View more
  12 in total

1. 

Authors:  凡 吴; 天晗 周; 凯宁 陆; 婷 潘; 烨钦 倪; 玲倩 赵; 可成 姜; 煜 张; 定存 罗
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

2.  Risk factors for lateral cervical lymph node metastasis in medullary thyroid carcinoma.

Authors:  Fan Wu; Tianhan Zhou; Kaining Lu; Ting Pan; Yeqin Ni; Lingqian Zhao; Kecheng Jiang; Yu Zhang; Dingcun Luo
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

3.  Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis.

Authors:  Zhe Xu Cao; Xin Weng; Jiang Sheng Huang; Xia Long
Journal:  Updates Surg       Date:  2022-07-12

4.  Lymph node metastases in pediatric medullary thyroid carcinoma.

Authors:  Jamie R Oliver; Kepal N Patel; Clifford M Chang; Chelsey K Baldwin; Preneet C Brar; Luc G T Morris; Babak Givi
Journal:  Surgery       Date:  2021-04-08       Impact factor: 4.348

5.  Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study.

Authors:  Xin Wu; Binglu Li; Chaoji Zheng
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Preoperative Serum Calcitonin Level and Ultrasonographic Characteristics Predict the Risk of Metastatic Medullary Thyroid Carcinoma: Functional Analysis of Calcitonin-Related Genes.

Authors:  Yi Fan; Haishan Xu; Meiyan Lv; Ning Li
Journal:  Dis Markers       Date:  2022-03-02       Impact factor: 3.434

7.  The Prediction of Metastases of Lateral Cervical Lymph Node in Medullary Thyroid Carcinoma.

Authors:  Tian-Han Zhou; Ling-Qian Zhao; Yu Zhang; Fan Wu; Kai-Ning Lu; Lin-Lin Mao; Ke-Cheng Jiang; Ding-Cun Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-17       Impact factor: 5.555

Review 8.  A Review of the Significance in Measuring Preoperative and Postoperative Carcinoembryonic Antigen (CEA) Values in Patients with Medullary Thyroid Carcinoma (MTC).

Authors:  Ioannis Passos; Elisavet Stefanidou; Soultana Meditskou-Eythymiadou; Maria Mironidou-Tzouveleki; Vasiliki Manaki; Vasiliki Magra; Styliani Laskou; Stylianos Mantalovas; Stelian Pantea; Isaak Kesisoglou; Konstantinos Sapalidis
Journal:  Medicina (Kaunas)       Date:  2021-06-11       Impact factor: 2.430

9.  Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.

Authors:  Liuqing Ye; Xi Zhou; Jie Lu; Yanzhong Wang; Xinyou Xie; Jun Zhang
Journal:  J Clin Lab Anal       Date:  2020-03-06       Impact factor: 2.352

10.  Risk Factors for Lateral Lymph Node Metastases in Patients With Sporadic Medullary Thyroid Carcinoma.

Authors:  Xin Wu; Binglu Li; Chaoji Zheng; Wei Liu; Tao Hong; Xiaodong He
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.